[DVAX] Dynavax Technologies Corporation


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 547.86 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 4.1 Change: 0.05 (1.23%)
Ext. hours: Change: 0 (0%)

chart DVAX

Refresh chart

Strongest Trends Summary For DVAX

DVAX is in the medium-term down -15% in 2 months and down -49% below S&P in 4 months and down -73% below S&P in 8 months. In the long-term down -82% in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops products to prevent and treat infectious and inflammatory diseases, and cancer. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a investigational adult hepatitis B vaccine which is in Phase III clinical trials. The company also develops DV1179, a TLR inhibitor of TLR 7 and TLR9 for the treatment of autoimmune and inflammatory diseases that is in Phase I clinical trials; AZD1419, a candidate drug for the treatment of asthma, which is in Phase I clinical trials; SD-101, a second-generation TLR 9 agonist for immunotherapy of cancer that is in Phase I clinical trials; and DV230, an adjuvant platform that is in preclinical studies. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the d

Fundamental Ratios
Shares Outstanding38.5 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -79.43% Sales Growth - Q/Q-72.46% P/E
P/E To EPS Growth P/S67.13 P/BV7.3 Price/Cash Per Share5.61
Price/Free Cash Flow-7.27 ROA-91.91% ROE-137.33% ROI
Current Ratio4.97 Quick Ratio Long Term Debt/Equity Debt Ratio0.27
Gross Margin Operating Margin-1271.85% Net Profit Margin-1263.31% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities140 K Cash From Investing Activities-10.52 M Cash From Operating Activities-24.14 M Gross Profit
Net Profit-26.22 M Operating Profit-26.45 M Total Assets112.17 M Total Current Assets101.98 M
Total Current Liabilities20.5 M Total Debt9.51 M Total Liabilities37.1 M Total Revenue630 K
Technical Data
High 52 week15.75 Low 52 week2.69 Last close3.38 Last change11.55%
RSI51.06 Average true range0.27 Beta1.07 Volume1.13 M
Simple moving average 20 days6.88% Simple moving average 50 days-8.07% Simple moving average 200 days-57.13%
Performance Data
Performance Week22.46% Performance Month-10.58% Performance Quart-57.16% Performance Half-67.93%
Performance Year-74.59% Performance Year-to-date-63.06% Volatility daily4.45% Volatility weekly9.94%
Volatility monthly20.37% Volatility yearly70.58% Relative Volume185.36% Average Volume1.64 M
New High New Low


2019-08-27 14:39:06 | Here's How to Find Top-Ranked Stocks Under $10 to Buy

2019-08-27 12:24:45 | We Think Dynavax Technologies NASDAQ:DVAX Has A Fair Chunk Of Debt

2019-08-19 09:53:01 | Dynavax Technologies Corporation DVAX Shares March Higher, Can It Continue?

2019-08-12 16:05:00 | Dynavax Announces Andrew Hack, M.D., Ph.D., Has Joined Board of Directors

2019-08-08 17:16:22 | Dynavax Technologies Corp DVAX Q2 2019 Earnings Call Transcript

2019-08-08 08:00:00 | Dynavax Technologies Announces Pricing of $70.1 Million Public Offering of Common Stock, Non Voting Preferred Stock and Warrants to Purchase Common Stock

2019-08-08 04:04:54 | Edited Transcript of DVAX earnings conference call or presentation 7-Aug-19 8:30pm GMT

2019-08-07 18:45:10 | Dynavax Technologies DVAX Reports Q2 Loss, Tops Revenue Estimates

2019-08-07 16:12:46 | Dynavax Technologies Announces Proposed Public Offering of Common Stock, Non-Voting Preferred Stock and Warrants to Purchase Common Stock

2019-08-07 16:01:00 | Dynavax Announces Second Quarter 2019 Financial Results

2019-07-24 16:05:00 | Dynavax Technologies to Report Second Quarter 2019 Financial Results and Host Conference Call on August 7

2019-07-23 11:00:00 | Are These 2 Beaten-Down Biotech Stocks Worth Buying?

2019-07-22 17:13:00 | Here's Why Dynavax Technologies Fell Again Today

2019-07-19 09:56:01 | Dynavax Technologies Sees Hammer Chart Pattern: Time to Buy?

2019-07-14 19:03:00 | 3 Biotech Stocks That Could Double Your Money

2019-07-11 11:55:02 | Dynavax: Last Chance to Make Good

2019-07-04 11:39:00 | Why Dynavax Technologies' Stock Tanked in June

2019-06-27 11:19:29 | Here’s What Hedge Funds Think About Dynavax Technologies Corporation DVAX

2019-06-03 16:05:00 | Dynavax to Present at the William Blair & Co. Annual Growth Stock Conference  

2019-06-03 14:15:00 | Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax’s SD-101 in Combination with KEYTRUDA® pembrolizumab; Data Presented Today at the 2019 ASCO Annual Meeting

2019-06-01 14:15:00 | Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDA® pembrolizumab for Patients with Head and Neck Squamous Cell Carcinoma at the 2019 ASCO Annual Meeting

2019-05-27 05:00:09 | Dynavax DVAX to Cut Jobs and Focus on Vaccine Business

2019-05-26 17:03:35 | The Week Ahead In Biotech: ASCO Presentations In The Spotlight

2019-05-24 18:10:00 | Here's Why Dynavax Technologies Is Tumbling

2019-05-24 17:41:13 | East Bay biotech pivoted to cancer, found new space — now CEO is leaving, 82 jobs are cut

2019-05-24 07:44:48 | The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice

2019-05-23 17:25:00 | Dynavax announces layoffs, CEO retirement

2019-05-23 16:45:00 | Dynavax Announces Strategic Restructuring to Focus on its Vaccine Business

2019-05-21 11:14:54 | Could The Dynavax Technologies Corporation NASDAQ:DVAX Ownership Structure Tell Us Something Useful?

2019-05-10 09:14:00 | Hopeful Signs for These 2 Small Biotech Stocks

2019-05-09 14:08:00 | Why Dynavax Technologies Stock Is Soaring Today

2019-05-09 13:33:33 | Is Dynavax Technologies Corporation DVAX A Good Stock To Buy?

2019-05-09 00:07:24 | Edited Transcript of DVAX earnings conference call or presentation 8-May-19 8:30pm GMT

2019-05-08 21:23:49 | Dynavax Technologies Corp DVAX Q1 2019 Earnings Call Transcript

2019-05-08 19:45:11 | Dynavax Technologies DVAX Reports Q1 Loss, Misses Revenue Estimates

2019-05-08 18:35:47 | Dynavax Technologies: 1Q Earnings Snapshot

2019-05-08 16:05:00 | Dynavax Announces First Quarter 2019 Financial Results

2019-05-08 14:30:00 | Dynavax Technologies Corp. to Host Earnings Call

2019-05-02 17:00:00 | Dynavax Announces First Patient Enrolled in Study of HEPLISAV-B® in Adults With End-Stage Renal Disease

2019-05-01 10:33:02 | Analysts Estimate Dynavax Technologies DVAX to Report a Decline in Earnings: What to Look Out for

2019-04-25 16:05:00 | Dynavax Technologies to Report First Quarter 2019 Financial Results and Host Conference Call on May 8

2019-04-18 16:05:00 | Dynavax to Present Data on Toll-like Receptor 9 Agonist SD-101 at the ASCO Annual Meeting 2019

2019-04-06 10:42:56 | Investors Who Bought Dynavax Technologies NASDAQ:DVAX Shares Three Years Ago Are Now Down 66%

2019-04-03 10:02:41 | After inking lease with cancer-fighting company, this new East Bay biotech project is full

2019-04-02 13:00:00 | Dynavax Presents Phase 1b Data on Inhaled DV281 TLR9 Agonist at the 2019 AACR Annual Meeting

2019-04-02 07:30:37 | The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial

2019-03-28 16:05:00 | Dynavax Announces European Medicines Agency Accepts Marketing Authorization Application for HEPLISAV-B® for Prevention of Hepatitis B in Adults

2019-03-21 06:30:00 | HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results

2019-03-20 16:20:00 | Dynavax to Present on Inhaled TLR9 Agonist DV281 at the AACR Annual Meeting 2019

2019-03-18 16:05:00 | Dynavax Exercises Option for $75 Million in Non-Dilutive Debt